- Company
- Trelegy 200 Ellipta may be prescribed at tertiary hospitals
- by Eo, Yun-Ho Jun 25, 2024 05:46am
- The double dose Trelegy Ellipta, which received approval in Korea for asthma, not COPD, may now be prescribed at general hospitals in Korea. According to industry sources, GSK Korea's Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) has passed the drug committees (DCs) of the Big 5 tertiary hospitals in Korea, including Sam
- Company
- 'Camzyos' receives DREC’s reconsideration decision
- by Eo, Yun-Ho Jun 25, 2024 05:46am
- The final decision was not reached on the first attempt. The path to getting 'Camzyos,' the first novel drug for obstructive hypertrophic cardiomyopathy (oHCM), listed for reimbursement seems to be challenging. According to the industry sources, BMS Korea’s Camzyos (mavacamten), a novel drug used to treat obstructive hypertrophic cardio
- Company
- K-Bios make bid into pancreatic cancer treatment environment
- by Son, Hyung-Min Jun 24, 2024 05:47am
- The domestic pharmaceutical and bio-industry has made a bid into the development of new drugs for pancreatic cancer through the use of combination therapy. Despite the development of various treatments to date, the five-year survival rate of pancreatic cancer has remained the lowest among the top 10 cancers, at 12.6%. Pancreatic cancer is diffic
- Company
- Pfizer reapplies for reimb listing of Vyndamax in Korea
- by Eo, Yun-Ho Jun 21, 2024 05:47am
- ‘Vyndamax,’ a new drug for transthyretin&160;amyloid cardiomyopathy (ATTR-CM), is again attempting reimbursement listing in Korea. According to industry sources, Pfizer Korea had recently submitted an application for the insurance reimbursement of Vyndamax, its new drug for transthyretin amyloid cardiomyopathy (ATTR-CM). Vyndamax f
- Company
- AprilBio licenses out novel drug to a U.S. firm
- by Son, Hyung-Min Jun 21, 2024 05:47am
- AprilBio, a company developing biopharmaceuticals, announced on June 20th that it has licensed out 'APB-R3,' an autoimmune diseases candidate, to the U.S.-based novel drug developer Evommune. It has been contracted for up to US$475 million (approximately KRW 655 billion), including a non-refundable upfront fee of US$15 million (KRW 20.7 bi
- Company
- JW Pharmaceutical’s new drugs enter clinical trials
- by Son, Hyung-Min Jun 21, 2024 05:46am
- JW Pharmaceutical is accelerating the development of innovative first-in-class drugs. Recently, the company's STAT3-targeted anticancer drug candidate entered Phase I clinical trials. In addition to targeted anticancer drugs, the company also owns first-in-class drug candidates in the fields of atopic dermatitis, hair loss, and blood cancer.
- Company
- ‘Treatment access improved for Lysosomal Storage Diseases'
- by Son, Hyung-Min Jun 20, 2024 05:48am
- "Lysosomal storage diseases show various symptoms throughout the body, making it difficult to diagnose the disease based on clinical manifestation alone. Therefore, it is important to diagnose it early and prevent the progression of symptoms with enzyme replacement therapy." On September 19, Sanofi held a press conference at the Lotte Hot
- Company
- ‘Long-term treatment for osteoporosis is now possible'
- by Son, Hyung-Min Jun 20, 2024 05:48am
- The improved reimbursement standards for osteoporosis drugs have created a treatment environment that promotes fracture prevention. Healthcare professionals have pointed out that the treatment continuation rate of osteoporosis patients has been low stressing the importance of continuous treatment to minimize the risk of fracture. On Sep
- Company
- HK inno.N and others license out jointly developed candidate
- by Kim, Jin-Gu Jun 20, 2024 05:48am
- 'IMB-101(OXTIMA),' a dual-antibody candidate jointly developed by HK inno. N, IMBiologics, and Y-Biologics, was licensed out to a U.S. biotech company specializing in new drug development. The contract amounts to US$940 million (approximately KRW 1.3 trillion), including an up-front payment of US$20 million (KRW 27.6 billion). HK inn
- Company
- K-pharma speeds up Keytruda biosimilar development...
- by Kim, Jin-Gu Jun 19, 2024 05:46am
- Biopharmaceutical companies in South Korea are fast-developing biosimilars referencing 'Keytruda (pembrolizumab),' which has ranked no.1 in global sales. Samsung Bioepis and Celltrion have initiated global phase 3 trials. Due to Keytruda’s leading position in global sales, competition is expected among the companies mentioned above, as
